Skip to main content

Supplementary Table 2 Cytofluorometric analyses of peripheral blood mononuclear cells on day 8 (A) and day 13 (B) of anti-CD4 treatment (data from one representative of three in vivo experiments).

From: Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-κB binding activity and TNF-α secretion of T cells

(A) Day 8
  Treatment
  PBS (n = 4) W3/25 (n = 2) OX35 (n = 4) RIB5/2 (n = 3)
Antigen (FACS) % MFI % MFI % MFI % MFI
Isotype control 0 ± 0.0 107 ± 9.0 4 ± 0.5 98 ± 2.0 1 ± 0.3 82 ± 3.3 0 ± 0.0 86 ± 7.7
CD3 70 ± 5.5 122 ± 1.7 47 ± 5.0 99 ± 1.5 31 ± 1.9* 93 ± 1.5* 28 ± 7.2* 95 ± 0.7*
CD8 21 ± 1.0 162 ± 1.3 27 ± 3.0 110 ± 1.5 33 ± 2.0* 109 ± 5.0* 39 ± 3.2* 111 ± 0.3*
CD4 (W3/25) 55 ± 3.2 116 ± 0.8 7 ± 2.5 98 ± 1.5 23 ± 1.7* 97 ± 1.2* 8 ± 1.5* 95 ± 0.7*
CD4 (OX35) 52 ± 7.5 150 ± 0.9 45 ± 8.0 93 ± 3.0 26 ± 4.1 122 ± 2.4 8 ± 1.2* 121 ± 1.0*
Mouse IgG 1 ± 0.3 105 ± 1.9 18 ± 2.0 101 ± 0.5 2 ± 0.3 79 ± 2.4* 1 ± 0.0 85 ± 3.2*
(B) Day 13
  Treatment
  PBS (n = 3) W3/25 (n = 4) OX35 (n = 4) RIB5/2 (n = 3)
Antigen (FACS) % MFI % MFI % MFI % MFI
Isotype control 1 ± 0.6 78 ± 1.3 2 ± 1.7 87 ± 4.1 1 ± 0.3 81 ± 3.7 1 ± 0.3 71 ± 1.7
CD3 53 ± 2.3 142 ± 0.6 44 ± 2.3 116 ± 3.0* 39 ± 2.5* 94 ± 1.0* 38 ± 1.5* 96 ± 2.0*
CD8 20 ± 3.8 144 ± 1.5 23 ± 1.7 128 ± 3.2* 30 ± 7.4 108 ± 1.6* 41 ± 2.3* 113 ± 0.9*
CD4 (W3/25) 46 ± 1.0 110 ± 1.9 28 ± 2.0* 109 ± 1.9 25 ± 2.9* 104 ± 1.6 20 ± 0.9* 106 ± 0.7
CD4 (OX35) 46 ± 0.7 154 ± 0.7 29 ± 3.8* 144 ± 5.9 23 ± 5.3* 102 ± 2.6* 17 ± 2.5* 116 ± 6.4*
Mouse IgG 4 ± 2.5 77 ± 2.5 9 ± 2.0 91 ± 3.5* 1 ± 0.2 82 ± 2.7 2 ± 0.0 76 ± 1.2
  1. Results of surface staining are expressed as the mean ± SEM of the percentage of positive cells and the mean fluorescence intensity (MFI). FACS = flow cytometry. *P ≤ 0.05 in comparison with PBS control.